Exploring a new long noncoding RNA's role in nerve pain
Official title: Identification of a Novel DRG-Specific Long Noncoding RNA and its Role in Neuropathic Pain
Funded at Rutgers Biomedical and Health Sciences · NIH-11161371 · Data updated 2026-11-12
This study is looking at a special type of RNA that might affect how we feel pain after nerve injuries, and it's for anyone interested in understanding more about neuropathic pain and finding better ways to manage it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | April 15, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $442,408 |
| NIH project number | 5R01NS117484-05 |
| Project ID | NIH-11161371 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing neuropathic pain due to peripheral nerve injuries.
✕Less likely to help
Patients with pain not related to nerve injuries or those with other underlying conditions may not benefit from this research.
What this research studies
This research investigates a specific long noncoding RNA (DS-lncRNA) that is believed to play a significant role in neuropathic pain following peripheral nerve injury. By utilizing advanced RNA sequencing techniques, the study aims to identify how the expression of this RNA is altered in pain-related areas of the nervous system, particularly the dorsal root ganglia. The researchers will explore the mechanisms by which DS-lncRNA influences pain sensitivity and may develop new strategies for managing neuropathic pain based on their findings.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for neuropathic pain, improving the quality of life for affected patients.
How similar studies have gone: While the role of long noncoding RNAs in pain is an emerging field, preliminary findings suggest that similar approaches have shown promise in understanding pain mechanisms.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Hu, Huijuan — Rutgers Biomedical and Health Sciences
- Study coordinator: Hu, Huijuan
Related research
Other NIH-funded projects on the same topics.
-
Peripheral nerve stimulation for chronic neuropathic pain in a new mechanistic trial
A study at Stanford tests whether a painless-sounding electrical nerve treatment helps people with long-standing neuropathic pain when added to standard care.
-
Keratinocytes and nerve pain in chemotherapy patients
A study tests a new approach to reduce painful nerve damage from chemotherapy by targeting skin cells called keratinocytes.
-
High-frequency brain stimulation for trigeminal neuropathic pain
A large, multi-site trial tests a non-invasive brain stimulation method to relieve chronic facial nerve pain for adults who have not found relief from other treatments.
-
Programmable lithium-delivery devices for pain relief without motor loss
A new bioelectronic system uses a safe lithium source and AI-powered control to deliver targeted pain relief for neuropathic pain, aiming to spare motor function.
-
Glial-nerve conversations in neuropathic pain and diabetes
This grant looks at how supportive brain and nerve cells communicate with pain-sensing neurons to understand and reduce chronic nerve pain in people.
-
Parmodulins with Low Abuse Potential for Neuropathic Pain
A new class of pain medicines called parmodulins is being studied to help people with nerve-pain pain without high abuse risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.